Document Detail


Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
MedLine Citation:
PMID:  19441109     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with core-binding factor (CBF) abnormalities.
METHODS: A total of 188 patients with CBF AML were analyzed. The frequency of secondary CBF AML was 9%.
RESULTS: Patients with secondary CBF AML were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF AML. Secondary CBF AML status appeared to have only marginal significance in multivariate analysis.
CONCLUSIONS: Matched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with secondary CBF AML.
Authors:
Gautam Borthakur; E Lin; Nitin Jain; Elihu E Estey; Jorge E Cortes; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Sherry Pierce; Hagop Kantarjian
Related Documents :
6849839 - Coexistent myelodysplasia and plasma cell neoplasia.
7514439 - 2chlorodeoxyadenosine therapy of patients with waldenström macroglobulinemia previousl...
272799 - Rapid cytoreduction in acute leukemia. management of cerebral leukostasis by cell phere...
8136289 - Clonal chromosomal abnormalities in fanconi's anaemia: what do they really mean?
7093939 - C-banding studies in acute nonlymphocytic leukemia.
12107559 - Splenectomy in patients with mixed myelodysplastic/myeloproliferative disease.
22086519 - The characteristics of stress cardiomyopathy in an ethnically heterogeneous population.
15335409 - Diagnosis and therapy of irritable bowel syndrome.
15010729 - Inhaled corticosteroids in copd: determinants of use and trends in patient persistence ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cancer     Volume:  115     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-07-10     Completed Date:  2009-08-17     Revised Date:  2014-10-04    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3217-21     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Core Binding Factors / metabolism*
Cytarabine / therapeutic use
Disease-Free Survival
Female
Humans
Leukemia, Myeloid, Acute / drug therapy,  genetics,  mortality*
Male
Middle Aged
Neoplasms, Second Primary / mortality*
Survival Analysis
Translocation, Genetic
Grant Support
ID/Acronym/Agency:
P30 CA016672/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Core Binding Factors; 04079A1RDZ/Cytarabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in hu...
Next Document:  Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung can...